Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Chcesz wydać pracę doktorską, habilitacyjną czy monografię? Zrób to w Wydawnictwie Borgis – jednym z najbardziej uznanych w Polsce wydawców książek i czasopism medycznych. W ramach współpracy otrzymasz pełne wsparcie w przygotowaniu książki – przede wszystkim korektę, skład, projekt graficzny okładki oraz profesjonalny druk. Wydawnictwo zapewnia szybkie terminy publikacji oraz doskonałą atmosferę współpracy z wysoko wykwalifikowanymi redaktorami, korektorami i specjalistami od składu. Oferuje także tłumaczenia artykułów naukowych, skanowanie materiałów potrzebnych do wydania książki oraz kompletowanie dorobku naukowego.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - Postępy Nauk Medycznych 8/2015, s. 597-602
*Andrzej Madejczyk, Tomasz Zapolski, Andrzej Wysokiński, Wojciech Brzozowski
Przezskórne zamknięcie uszka lewego przedsionka u pacjentów z migotaniem przedsionków
Transcatheter left atrial appendage occlusion in patients with atrial fibrillation
Chair and Department of Cardiology, Medical University, Lublin
Head of Department: prof. Andrzej Wysokiński, MD, PhD
Streszczenie
Migotanie przedsionków jest jedną najczęściej występujących arytmii serca. Obserwuje się go u ok. 1-2% ogólnej populacji, a częstość jego występowania wzrasta wraz z wiekiem. Do roku 2050 przewiduje się trzykrotny wzrost zachorowalności na to schorzenie. U pacjentów z migotaniem przedsionków występuje szczególnie duże ryzyko wystąpienia zatorowości obwodowej a w szczególności niedokrwiennego udaru mózgu. Wyróżnia się dwa główne sposoby zapobiegania udarom mózgu związanym z występowaniem migotania przedsionków. Pierwszy z nich to stosowanie przewlekłej terapii przeciwzakrzepowej, a drugi to zamknięcie uszka lewego przedsionka jako źródła materiału zatorowego. W pracy przedstawiono systemy służące do przezskórnego zamykania uszka lewego przedsionka u chorych z migotaniem przedsionków. Opisano wskazania do tego typu zabiegów oraz wyniki dostępnych randomizowanych badań.
Summary
Atrial fibrillation is one of the most common cardiac arrhythmias. It affects 1-2% of the total population, and the frequency of its incidence increases with age. The threefold increase in the incidence of this disease is projected by 2050. In patients with atrial fibrillation there is a high risk of embolism in particular ischemic stroke. There are two main types of preventing the impact on the brain associated with occurrence of atrial fibrillation. The first is the use of chronic anticoagulant therapy, and the second is closing the left atrium appendage as a source of embolic material. The paper presents systems for transcatheter closing of the left atrial appendage in patients with atrial fibrillation. Describes the indications for this type of treatment and the results of available randomized trials.
Introduction
Atrial fibrillation is one the most common significant heart arrhythmias. It affects 1-2% of the total population, and the frequency of its incidence increases with age (1-4). A triple increase in the incidence of this disorder is projected by 2050 (5). There occurs particularly high risk of peripheral embolism and, in particular, ischemic stroke in patients with atrial fibrillation. The risk of stroke in patients with atrial fibrillation of non valvular origin is about 5% per year (6). In the research by Framigham, it has been shown, however, that the mortality rate of patients due to a stroke resulting from the atrial fibrillation is significantly higher in comparison to the strokes not connected with arrhythmia (7). This fact indicates the necessity of effective treatment and prevention in case of the occurrence of stroke in these patients. There are two main types of preventing the impact on the brain associated with occurrence of atrial fibrillation. The first is the use of chronic anticoagulant therapy, and the second is closing the left atrium appendage as a source of embolic material. The closure may be performed with surgical, thoracoscopic or percutaneous method. Randomized clinical studies show that the use of oral anticoagulant therapy is an effective method to reduce the risk of embolism and ischemic stroke. Sometimes, however, it is not fully exploited in patients with atrial fibrillation because of the risk of bleeding, contraindications or the lack of cooperation on the part of the patient (8-13). One of the most modern and dynamically developed methods used in the prevention of stroke in patients with atrial fibrillation is transcatheter atrial appendage occlusion. This method, however, is recommended only for patients unable to use chronic anticoagulant therapy.
The anatomy of the left atrial appendage
The left atrial appendage is the remnant of the embryological left atrium. It is a tubular structure with various patches and very variable morphology. Its complicated structure is conducive to the blood retention. It is especially evident during atrial fibrillation. The appendage consists of a very soft and thin “paper wall” and its ostium of very variable size from 5-40 mm is located between the mitral ring and the left upper lung vein. Its morphology can be very diverse and may resemble a shape of: a cactus, hen comb, sleeve or a cauliflower (14, 15). Echocardiographic studies have shown that in patients with atrial fibrillation of non-valvular origin, in 90% of cases the thrombus locates in the left atrium appendage. It results from the decrease in the speed of the blood flow, its stagnation, enlargement of the cavity and the increased activity of the platelets adhesion molecules (16-18).
The history of left atrial appendage occlusion
The concept of closing the left atrium appendage in patients with atrial fibrillation of non-valvular origin is based on the assumption that only 10% of the thrombi does not arise in the left atrium appendage. In conclusion, its exclusion as a potential source of embolic materials should greatly reduce the risk of ischemic stroke and pulmonary embolism. This is confirmed by the observations of patients with atrial fibrillation and congenital absence of the left atrial appendage, where the risk of embolic episodes is relatively small, though it has not been exactly estimated (19-27). Incidental occlusion treatments or resection of the left atrium appendage during the cardio surgery operations have been carried out for many years. In the literature the first of such cases was described by Madden already in 1949 (28). The effectiveness of the surgical resection of left atrium appendage methods in the prevention of stroke was described in patients undergoing coronary artery bypass surgery in a randomized study of LAAOS (LAA Occlusion Study) (29). However, this method is only additional, on the occasion of other cardio surgeries rather than as a standalone procedure. In recent times, occlusion systems have been developed using the electrocardiographic guided thoracoscopic technique (30), and special epicardial stitches led by the magnet (31). At different stages of the research there are other minimally invasive surgical and transcutaneous systems such as Aegis, AtriClip, Cardioablate.
The first transcatheter device for left atrial appendage occlusion was the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion device). It was designed as a nitinol valve mask frame covered with a polytetrafluoroethylene membrane. The system was introduced to the left atrial appendage by venous system and interventricular septum through appropriately profiled interatrial vascular sheath of diameter of 12F. Settling in the appendage was enabled due to the hooks located on the wires of occluder and passing out through the membrane.
The first implantation of the PLAATO system in a man took place on 30 August 2001 and was conducted by Sievert and Lesh (32). The efficiency of the system has been confirmed in small clinical trials, however, due to the difficult technique of implantation and observed side effects of the system it has been withdrawn from the market in 2006. The second system which was used for the transcutaneous left atrium appendage occlusion was AMPLATZER, designed for atrial septal defect occlusion with two opposite disks. The first treatment with the use of this system was conducted on June 16, 2002 by Bernhard Meier. The treatment was carried out with a local anesthesia (33). In the following years, AMPLATZER was redesigned to match left atrium appendage. In 2008 a dedicated to the left atrial appendage occlusion Cardiac Amplatzer was introduced (ACP, St. Jude, USA) together with a specially developed bringing catheter. The system received CE mark in December 2008. The ACP system is built with nitinol meshwork covered with polyester material. It consists of three parts: central panel, carpal tunnel and disc. The disc has the task of ostium left atrium appendage occlusion. With the usage of the lobe, the position of the occluder stabilizes on the surface of small hooks. The system is available in sizes from 16 to 30 mm. In 2012, a new version of the occluder ACP called AMULET was introduced. The old platform remained the same but the lobe and isthmus was redesigned increasing the amount of catches so as to improve the fixation of the system and its effectiveness to reduce the risk of formation of thrombi. The AMULET system was, however, withdrawn from the market to successive improvements.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

Piśmiennictwo
1. Stewart S, Hart C, Hole D, McMurray J: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-521.
2. Go A, Hylek E, Phillips K et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Heeringa J, van der Kuip D, Hofman A et al.: Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953.
4. Kannel WB, Benjamin EJ: Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92: 17-40.
5. Miyasaka Y, Barnes ME, Gersh BJ et al.: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
6. Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
7. Lin HJ, Wolf PA, Kelly-Hayes M et al.: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
8. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
9. Waldo AL, Becker RC, Tapson VF, Colgan KJ: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
10. Bungard TJ, Ghali WA, Teo KK et al.: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46.
11. Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-121S.
12. Kirchhof P, Ammentorp B, Darius H et al.: Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the prvention of thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14.
13. Laroche C, Dan GA, Santini M et al.: A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319.
14. Veinot JP, Harrity PJ, Gentile F et al.: Anatomy of the Normal Left Atrial Appendage. A Quantitative Study of Age-Related Changes in 500 Autopsy Hearts: Implications for Echocardiographic Examination. Circulation 1997; 96: 3112-3115.
15. Mugge A, Kuhn H, Nikutta P et al.: Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994; 23: 599-607.
16. Pollick C, Taylor D: Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation 1991; 84: 223-231.
17. Madden JL: Resection of the left auricular appendix: a prophylaxis for recurrent arterial emboli. J Am Med Assoc 1949; 140: 769-772.
18. Handke M, Harloff A, Hetzel A et al.: Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation – a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr 2005; 18: 1366-1372.
19. Rosso R, Vexler D, Viskin S, Aviram G: Congenital absence of left atrial appendage. J Cardiovasc Electrophysiol 2014; 25: 795.
20. Tsai L, Chen J, Lin L, Yang Y: Role of transesophageal echocardiography in detecting left atrial thrombus and spontaneous echo contrast in patients with mitral valve disease or non-rheumatic atrial fibrillation. J Formos Med Assoc 1990; 89: 270-274.
21. Manning W, Weintraub R, Waksmonski C et al.: Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med 1995; 123: 817-822.
22. Stoddard M, Dawkins P, Prince C, Ammash N: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-459.
23. Tsai L, Lin L, Teng J, Chen J: Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol 1997; 58: 163-169.
24. Stoddard M, Singh P, Dawn B, Longaker R: Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J 2003; 145: 676-682.
25. Bernhardt P, Schmidt H, Hammerstingl C et al.: Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol 2004; 94: 801-804.
26. Tang R, Dong J, Zhang Z et al.: Comparison of contrast enhanced 64-slice computed tomography and transesophageal echocardiography in detection of left atrial thrombus in patients with atrial fibrillation. J Interv Card Electrophysiol 2008; 22: 199-203.
27. Yamashita E, Takamatsu H, Tada H et al.: Transesophageal echocardiography for thrombus screening prior to left atrial catheter ablation. Circ J 2010; 74: 1081-1086.
28. Madden J: Resection of the left auricular appendix: a prophylaxis for recurrent arterial emboli. J Am Med Assoc 1949; 140: 769-772.
29. Healey JS, Crystal E, Lamy A et al.: Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293.
30. Friedman PA, Asirvatham SJ, Dalegrave C et al.: Percutaneous epicardial left atrial appendage closure: preliminary results of an electrogram guided approach. J Cardiovasc Electrophysiol 2009; 20: 908-915.
31. Shetty R, Leitner J, Zhang M: Percutaneous catheter-based left atrial appendage ligation and management of periprocedural left atrial appendage perforation with the LARIAT suture delivery system. J Invasive Cardiol 2012; 24: E289-293.
32. Sievert H, Lesh MD, Trepels T et al.: Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105: 1887-1889.
33. Meier B, Palacios I, Windecker S et al.: Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60: 417-422.
34. Holmes DR, Reddy VY, Turi ZG et al.: PROTECT AF Investigators.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrialfibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542.
35. Reddy VY, Doshi SK, Sievert H et al.: Percutaneous left atrialappendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127: 720-729.
36. Reddy VY: Long term results of PROTECT AF: the mortality effects of left atrial appendage closure versus warfarin for stroke prophylaxis in AF. Presented at: Heart Rhythm Society 34th Annual Scientific Sessions; May 9, 2013; Denver, CO.
37. Holmes DR, Kar S, Price MJ et al.: Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial. Am Coll Cardiol 2014; 64(1): 1-12.
38. Reddy VY, Holmes D, Shephal K et al.: Safety of Percutaneous Left Atrial Appendage Closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in PatientsWith AF (PROTECT AF) Clinical Trial and the Continued Access Registry. Circulation 2011; 123: 417-424.
39. Camm AJ, Lip GYH, De Caterina R et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747.
40. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/default.htm.
41. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm046719.htm.
otrzymano: 2015-06-08
zaakceptowano do druku: 2015-07-09

Adres do korespondencji:
*Andrzej Madejczyk
Chair and Department of Cardiology,
Medical University
ul. Jaczewskiego 8, 20-954 Lublin
tel. +48 (81) 724-41-51
amadejczyk@wp.pl

Postępy Nauk Medycznych 8/2015
Strona internetowa czasopisma Postępy Nauk Medycznych

Pozostałe artykuły z numeru 8/2015: